A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
Status
Conditions
Treatments
Details and patient eligibility
About
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19. This study is intended to be registered with the participants who:
- Have taken PAXLOVID PACK and have no history of using this medicine.
- Are 12 years and older
All participants will receive PAXLOVID, a standard treatment for COVID-19. Participants will take PAXLOVID 2 times a day by mouth or as prescribed.
We will examine the experiences of people taking PAXLOVID. This will help us determine if PAXLOVID is safe and effective.
Participants will be followed up for 28 days after taking PAXLOVID. During this time, participants will be closely watched for the safety and effects of PAXLOVID.
Full description
This is a multicenter cohort study to be conducted in individuals with SARS-CoV-2 infection who are treated with this product, and the investigator will enter the information required in this study in the case report forms (CRFs) based on the information obtained through medical records.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Subjects who are administered PAXLOVID PACK and have no history of using this drug.
Exclusion criteria
- There are no exclusion criteria for this study.
Trial design
3,346 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Pfizer CT.gov Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal